Efficacy Study of Adalimumab to Treat Interstitial Cystitis

NCT ID: NCT01295814

Last Updated: 2015-07-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-03-31
• Study Completion Date: 2013-07-31

Brief Summary

The purpose of this study is to evaluate an investigational treatment for interstitial cystitis. Interstitial cystitis is a chronic bladder disease that includes the following symptoms: Urinary frequency during the day,urinary frequency at night, urinary urgency and bladder discomfort relieved by voiding.

Presently, there is no cure for interstitial cystitis. The response to current treatments is poor. Patients with interstitial cystitis have a poorer quality of life. The cause of interstitial cystitis is unknown. This study is evaluating the drug Humira® (adalimumab) for improving the symptoms of patients with interstitial cystitis. Humira® is an injectable anti-inflammatory medication that has been available for use since December 31, 2002. Humira® has been FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease. These diseases have similar characteristics to interstitial cystitis. This study will evaluate an investigational use of Humira® for the treatment of interstitial cystitis.

Detailed Description

Interstitial cystitis (IC) is a chronic disabling bladder syndrome characterized by urinary frequency, nocturia, urinary urgency, and pain with bladder filling-relieved by emptying. There is no cure for IC and the treatment options are suboptimal. Patients with IC report significant negative effects on their physical and mental quality of life. The etiology of IC is unknown. Certain aspects of IC suggest that autoimmunity may play a role in initiating or sustaining the chronic inflammatory response. Bladder biopsies of patients with IC demonstrate an increase number of mast cells. Mast cell activation with the release of tumor necrosis factor (TNF) may mediate this bladder inflammation. Humira® (adalimumab) is a medication that blocks the effect of TNF. Humira® (adalimumab) is FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease. These diseases are similar to IC. In this study, the hypothesis being tested is that Humira® (adalimumab) will show efficacy at reducing the symptoms of IC.

Conditions

Interstitial Cystitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

adalimumab

Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks

Group Type: EXPERIMENTAL

Adalimumab

Intervention Type: DRUG

80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

Inactive drug

Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks

Group Type: PLACEBO_COMPARATOR

inactive drug

Intervention Type: OTHER

80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

Interventions

Adalimumab

80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

Intervention Type: DRUG

inactive drug

80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

Intervention Type: OTHER

Other Intervention Names

Humira; placebo

Eligibility Criteria

Inclusion Criteria

• Males or females ≥18 and ≤ 65 years of age previously diagnosed with Interstitial Cystitis
• Currently have symptoms of urinary urgency, frequency or pain for more than 6 months
• Urinating at least 7 times a day or having some urgency or pain (measured on linear analog scales)
• Must be post-menopausal or surgically sterile or willing to use an adequate form of birth control
• Not pregnant or lactating
• Capable of voiding independently
• Willing to provide informed consent to participate

Exclusion Criteria

• Have symptoms that are presently relieved on other medications for interstitial cystitis
• Have absence of nocturia
• Have symptoms that are relieved by antimicrobials or antibiotics.
• Have a body mass index (BMI) of >39 kg/m2
• Have uncontrolled hypertension
• Have Type I or type 2 diabetes
• Have active Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) infection, or who are known carriers (Hepatitis B) at Screening
• Have a positive tuberculosis test at screening
• Have had a urinary tract infection for 6 weeks
• Have had bacterial cystitis in previous 3 months
• Have had previous exposure to Humira® (adalimumab)
• Have taken investigational medication within 30 days of screening
• Have any other condition/disease which, in the opinion of the investigator, could compromise subject safety or confound the interpretation of study results
• Are unable or unwilling to comply with protocol requirements

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: collaborator

ICStudy, LLC

OTHER

Sponsor Role: lead

Responsible Party

Philip C. Bosch, M.D.

Urologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Philip C Bosch, MD

Role: PRINCIPAL_INVESTIGATOR

Locations

Philip C. Bosch, MD

Escondido, California, United States

Countries

United States

References

Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014 Jan;191(1):77-82. doi: 10.1016/j.juro.2013.06.038. Epub 2013 Jun 20.

Reference Type: RESULT

PMID: 23792149 (View on PubMed)

Imamura M, Scott NW, Wallace SA, Ogah JA, Ford AA, Dubos YA, Brazzelli M. Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis. Cochrane Database Syst Rev. 2020 Jul 30;7(7):CD013325. doi: 10.1002/14651858.CD013325.pub2.

Reference Type: DERIVED

PMID: 32734597 (View on PubMed)

Other Identifiers

IMM 10-0061

Identifier Type: -

Identifier Source: org_study_id